| Literature DB >> 34359795 |
Laurie Spehner1,2, Jihane Boustani3, Luc Cabel4, Jérôme Doyen5, Angélique Vienot1,2,6, Christophe Borg1,2,6, Stefano Kim1,2,6,7.
Abstract
Squamous cell carcinoma of the anus is an orphan disease, and after more than three decades of no substantial advances in disease knowledge and treatment, it is finally gaining momentum with the arrival of a taxane-based chemotherapy and immunotherapy. Currently, about 20 combination clinical trials with an anti-PD1/L1 are ongoing in localized and advanced stages, in association with radiotherapy, chemotherapy, tumor vaccines, anti-CTLA4, anti-EGFR, or antiangiogenic molecules. Moreover, a new biomarker with high sensitivity and specificity such as HPV circulating tumor DNA (HPV ctDNA) by liquid biopsy, is improving not only the prognostic measurement but also the treatment strategy guidance for this disease. Finally, better understanding of potential targets is reshaping the present and future clinical research in this unique, HPV genotype-16-related disease in the great majority of patients.Entities:
Keywords: anal carcinoma; biomarkers; chemotherapy; immunotherapy; research; trials
Year: 2021 PMID: 34359795 DOI: 10.3390/cancers13153895
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639